Lysergide d-tartrate

Lysergide d-tartrate
Identifiers
	IUPAC name (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(2S,3S)-2,3-dihydroxybutanedioic acid;
CAS Number	32426-57-6;
ChemSpider	180710;
UNII	7WNP51KA7M;
Chemical and physical data
Formula	C24H31N3O7
Molar mass	473.526 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1[C@]2(C(C=3C=4C(C2)=CNC4C=CC3)=C[C@@H](C(N(CC)CC)=O)C1)[H].[C@H]([C@@H](C(O)=O)O)(C(O)=O)O;
	InChI InChI=InChI=1S/C20H25N3O.C4H6O6/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14;5-1(3(7)8)2(6)4(9)10/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t14-,18-;1-,2-/m10/s1; Key:HQMPRARIZOUKRO-JDQBHMBOSA-N;

Lysergide d-tartrate (MM120) is an investigational new drug that was granted breakthrough therapy status for the treatment of Generalized Anxiety Disorder by the FDA in March 2024.^[1] It is a salt of lysergide.^[2]^[3]

References[edit]